Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells

Molecular Medicine Reports

Volumn 2, Issue 5, 2009, Pages 819-824

  Xu, Guotai ^a   Zhang, Cai ^a   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Dominant negative; Invasion; Lung cancer; Signal transducer and activator of transcription 3

Indexed keywords

CYCLIN D1; GELATINASE A; PROTEIN BCL XL; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; METASTASIS; TRANSCRIPTION INITIATION;

EID: 69249203685     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000178     Document Type: Article

References (23)

1. Lee GY, Jang JS, Lee SY, et al: XPC polymorphisms and lung cancer risk. Int J Cancer 115: 807-813, 2005. (Pubitemid 40776705)
2. Shih JY, Tsai MF, Chang TH, et al: Tanscription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 11: 8070-8078, 2005.
3. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008. (Pubitemid 351720831)
4. Rawlings JS, Rosler KM and Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 117: 1281-1283, 2004.
5. Alvarez JV, Greulich H, Sellers WR, Meyerson M and Frank DA: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66: 3162-3168, 2006.
6. Garcia R, Bowman TL, Niu G, et al: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001. (Pubitemid 32531347)
7. Leong PL, Andrews GA, Johnson DE, et al: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 100: 4138-4143, 2003.
8. Sun X, Zhang J, Wang L and Tian Z: Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Letters 262: 201-213, 2008.
9. Gouilleux-Gruart V, Gouilleux F, Desaint C, et al: STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87: 1692-1697, 1996. (Pubitemid 26068885)
10. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K and Murai M: Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168: 762-765, 2002. (Pubitemid 34793359)
11. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560, 2004. (Pubitemid 38658421)
12. Kahari VM and Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31: 34-45, 1999. (Pubitemid 29134483)
13. Wang T, Niu G, Kortylewski M, et al: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48-54, 2004. (Pubitemid 38524698)
14. Azzam HS, Arand G, Lippman ME and Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85: 1758-1764, 1993. (Pubitemid 23320847)
15. Chetty C, Bhoopathi P Joseph P, Chittivelu S, Rao JS and Lakka S: Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5: 2289-2299, 2006. (Pubitemid 44530466)
16. Zhang X, Zhang J, Wei H and Tian Z: STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol Rep 17: 1377-1382, 2007.
17. Zhang X, Zhang J, Wang L, Wei H and Tian Z: Therapeutic effects of STAT3-decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 7: 149-159, 2007. (Pubitemid 47470219)
18. Caldenhoven E, van Dijk TB, Solari R, et al: STAT3ß, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem 271: 13221-13227, 1996. (Pubitemid 26175904)
19. Niu G, Shain KH, Huang M, et al: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61: 3276-3280, 2001. (Pubitemid 32695012)
20. Jiang W, Sun R, Wei H and Tian Z: Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of toll like receptor 4 expression on macrophages. Proc Natl Acad Sci USA 102: 17077-17082, 2005. (Pubitemid 41692686)
21. Wei D, Le X, Zheng L, et al: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329, 2003. (Pubitemid 36194328)
22. Xiong H, Zhang ZG, Tian XQ, et al: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10: 287-297, 2008. (Pubitemid 351328587)
23. Buettner R, Huang M, Gritsko T, et al: Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5: 823-832, 2007. (Pubitemid 47294810)